Compare Koninklijke Philips NV (PHG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs State Street SPDR S&P Biotech ETF — how do they compare? Koninklijke Philips NV trades at $24.94 (market cap $24.84B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: Koninklijke Philips NV pays a 4.01% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Koninklijke Philips NV nearer its low. Which is the better fit depends on your goals.
| PHG | XBI | |
|---|---|---|
Market Cap | $24.84B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $32.91 | $169.55 |
52-Week Low | $25.02 | $93.43 |
Enterprise Value | $31.44B | — |
Dividend Yield | 4.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $25.29, down 2.32% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.57 versus $0.40 expected, continuing a trend of profitability after a turnaround from losses in prior years. Recent news highlights product launches in health technology and a $33.7 million award for AI-enabled stroke care (Business Wire, 2026-08-26).
The outlook is mixed: fundamentals show improving margins and cash flow, but technical indicators and a majority hold analyst rating suggest near-term caution. Key risks include competitive pressures and execution of growth initiatives, while institutional buying activity indicates underlying confidence.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
